Dongyang Liu

List of Publications by Year
in descending order

		1040056	345221
39 papers	**2,509** citations	**9** h-index	**36** g-index
40 all docs	**40** docs citations	**40** times ranked	**6400** citing authors

#	Article	IF	Citations
1	In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, 2020, 71, 732-739.	5.8	2,111
2	Current trends in drug metabolism and pharmacokinetics. Acta Pharmaceutica Sinica B, 2019, 9, 1113-1144.	12.0	147
3	Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. Acta Pharmaceutica Sinica B, 2020, 10, 1216-1227.	12.0	40
4	Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects. British Journal of Clinical Pharmacology, 2021, 87, 2711-2722.	2.4	19
5	Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects. Cancer Chemotherapy and Pharmacology, 2014, 73, 721-727.	2.3	17
6	Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model. Frontiers in Pharmacology, 2020, 11, 574720.	3.5	16
7	Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 441-454.	2.5	15
8	Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method. European Journal of Pharmaceutical Sciences, 2021, 158, 105584.	4.0	12
9	A unified strategy in selection of the best allometric scaling methods to predict human clearance based on drug disposition pathway. Xenobiotica, 2016, 46, 1105-1111.	1.1	10
10	Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women. Biopharmaceutics and Drug Disposition, 2020, 41, 248-267.	1.9	10
11	Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. Clinical Drug Investigation, 2019, 39, 643-651.	2.2	9
12	Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. European Journal of Pharmaceutical Sciences, 2020, 147, 105281.	4.0	9
13	Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process. Clinical Pharmacokinetics, 2017, 56, 925-939.	3.5	7
14	A high-performance liquid chromatography–tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple-dose pharmacokinetic study. Biomedical Chromatography, 2018, 32, e4324.	1.7	7
15	A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus. European Journal of Pharmaceutical Sciences, 2019, 136, 104942.	4.0	7
16	Development of an HPLC–MS/MS method to determine janagliflozin in human plasma and urine: application in clinical study. Bioanalysis, 2018, 10, 1439-1454.	1.5	6
17	Development of a simple HPLC–MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. Biomedical Chromatography, 2019, 33, e4420.	1.7	6
18	Response to Jia and Wang. Clinical Infectious Diseases, 2020, 73, 352-353.	5.8	6

#	ARTICLE	IF	CITATIONS
19	Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients. Frontiers in Pharmacology, 2020, 11, 585021.	3.5	6
20	Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. European Journal of Pharmaceutical Sciences, 2021, 159, 105704.	4.0	6
21	Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naÃ¯ve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial. EClinicalMedicine, 2021, 42, 101185.	7.1	5
22	Reply to Wolowich and Kwon. Clinical Infectious Diseases, 2021, 72, 1678-1680.	5.8	4
23	Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients. Biopharmaceutics and Drug Disposition, 2021, 42, 24-34.	1.9	4
24	Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. Frontiers in Pharmacology, 2020, 11, 602880.	3.5	4
25	A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30â€"90â€‰mg in healthy Chinese volunteers. Xenobiotica, 2017, 47, 592-599.	1.1	3
26	Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19. Science China Life Sciences, 2021, 64, 660-663.	4.9	3
27	Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes. Frontiers in Endocrinology, 2021, 12, 694390.	3.5	3
28	Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population. Current Drug Metabolism, 2020, 21, 534-540.	1.2	3
29	Simultaneous determination of imigliptin and its three metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1002, 300-312.	2.3	2
30	Metabolites characterization of a novel DPP-4 inhibitor, imigliptin in humans and rats using ultra-high performance liquid chromatography coupled with synapt high-resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 189-200.	2.8	2
31	Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. European Journal of Clinical Pharmacology, 2021, 77, 583-593.	1.9	2
32	Development of a Virtual Chinese Pediatric Population Physiological Model Targeting Specific Metabolism and Kidney Elimination Pathways. Frontiers in Pharmacology, 2021, 12, 648697.	3.5	2
33	Characterizing the Physicochemical Properties of Two Weakly Basic Drugs and the Precipitates Obtained from Biorelevant Media. Pharmaceutics, 2022, 14, 330.	4.5	2
34	Simultaneous determination of TPN729 and its five metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2018, 151, 91-105.	2.8	1
35	A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 166, 20-29.	2.8	1
36	Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19. Current Drug Metabolism, 2020, 21, 427-435.	1.2	1

#	ARTICLE	IF	CITATIONS
37	Reduction effect of oral pravastatin on the acute phase response to intravenous zoledronic acid: protocol for a real-world prospective, placebo-controlled trial. BMJ Open, 2022, 12, e060703.	1.9	1
38	Application of LCâ€"MS/MS method for determination of dihydroartemisin in human plasma in a pharmacokinetic study. Bioanalysis, 2020, 12, 1635-1646.	1.5	0
39	Toward Greater Insights on Applications of Modeling and Simulation in Pregnancy. Current Drug Metabolism, 2020, 21, 722-741.	1.2	0